Mizuho analyst Difei Yang last night initiated coverage of uniQure with a Buy rating and $67 price target. The analyst sees uniQure as one of the best gene therapy companies with a "promising" pipeline of indications. A pivotal trial of AMT-061 for the treatment of Hemophilia B is underway and the product could be "first and best-in-class," given strong efficacy and safety achieved in clinical trials so far, Yang tells investors in a research note. Further, following a recent equity offering, uniQure is in solid financial position with a cash runway into 2022, adds the analyst.